Published in Pharm Res on June 06, 2007
Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm (2008) 7.67
Delivery materials for siRNA therapeutics. Nat Mater (2013) 3.70
Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem Soc Rev (2012) 3.34
Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape. Nat Biotechnol (2013) 2.81
Nanomedicine--challenge and perspectives. Angew Chem Int Ed Engl (2009) 2.74
Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities. Science (2012) 2.73
Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy. Theranostics (2012) 2.35
Tumour-targeted nanomedicines: principles and practice. Br J Cancer (2008) 1.81
Tunable bifunctional silyl ether cross-linkers for the design of acid-sensitive biomaterials. J Am Chem Soc (2010) 1.69
Intracellular drug delivery by poly(lactic-co-glycolic acid) nanoparticles, revisited. Mol Pharm (2009) 1.61
Development of multifunctional nanoparticles for targeted drug delivery and noninvasive imaging of therapeutic effect. Curr Drug Discov Technol (2009) 1.60
In vivo gene delivery by nonviral vectors: overcoming hurdles? Mol Ther (2012) 1.59
Engineering of hetero-functional gold nanorods for the in vivo molecular targeting of breast cancer cells. Nano Lett (2009) 1.57
Liposome: classification, preparation, and applications. Nanoscale Res Lett (2013) 1.41
Extracellularly activated nanocarriers: a new paradigm of tumor targeted drug delivery. Mol Pharm (2009) 1.38
pH-Responsive nanoparticles for drug delivery. Mol Pharm (2010) 1.33
Action and reaction: the biological response to siRNA and its delivery vehicles. Mol Ther (2012) 1.18
Reductively responsive siRNA-conjugated hydrogel nanoparticles for gene silencing. J Am Chem Soc (2012) 1.17
Physical and chemical strategies for therapeutic delivery by using polymeric nanoparticles. Pharmacol Rev (2012) 1.15
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev (2015) 1.08
pH-sensitive poly(histidine)-PEG/DSPE-PEG co-polymer micelles for cytosolic drug delivery. Biomaterials (2012) 1.08
Enhancing the Clinical Potential of AAV Vectors by Capsid Engineering to Evade Pre-Existing Immunity. Front Microbiol (2011) 1.08
Small-molecule delivery by nanoparticles for anticancer therapy. Trends Mol Med (2010) 1.07
Chemical basis of interactions between engineered nanoparticles and biological systems. Chem Rev (2014) 1.07
Engineering biomaterial systems to enhance viral vector gene delivery. Mol Ther (2011) 1.07
HER-2-targeted nanoparticle-affibody bioconjugates for cancer therapy. ChemMedChem (2008) 1.03
Recent advances in stealth coating of nanoparticle drug delivery systems. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2012) 1.02
Zwitterionic chitosan derivatives for pH-sensitive stealth coating. Biomacromolecules (2010) 1.00
Low molecular-weight chitosan as a pH-sensitive stealth coating for tumor-specific drug delivery. Mol Pharm (2012) 1.00
Targeting of tumor-associated macrophages made possible by PEG-sheddable, mannose-modified nanoparticles. Mol Pharm (2013) 0.97
Endosomal escape and transfection efficiency of PEGylated cationic liposome-DNA complexes prepared with an acid-labile PEG-lipid. Biomaterials (2012) 0.97
Poly(ethylene glycol) with observable shedding. Angew Chem Int Ed Engl (2010) 0.96
Biomolecular corona on nanoparticles: a survey of recent literature and its implications in targeted drug delivery. Front Chem (2014) 0.95
Inorganic nanoparticles for multimodal molecular imaging. Mol Imaging (2011) 0.95
An efficient targeted drug delivery through apotransferrin loaded nanoparticles. PLoS One (2009) 0.95
Will nanotechnology influence targeted cancer therapy? Semin Radiat Oncol (2011) 0.95
New functional degradable and bio-compatible nanoparticles based on poly(malic acid) derivatives for site-specific anti-cancer drug delivery. Int J Pharm (2011) 0.91
Drug delivery: Stealth particles give mucus the slip. Nat Mater (2009) 0.91
Nanomedicine for drug targeting: strategies beyond the enhanced permeability and retention effect. Int J Nanomedicine (2014) 0.88
Decreased reticuloendothelial system clearance and increased blood half-life and immune cell labeling for nano- and micron-sized superparamagnetic iron-oxide particles upon pre-treatment with Intralipid. Biochim Biophys Acta (2013) 0.87
Nanomedicine in GI. Am J Physiol Gastrointest Liver Physiol (2010) 0.87
In vitro performance of lipid-PLGA hybrid nanoparticles as an antigen delivery system: lipid composition matters. Nanoscale Res Lett (2014) 0.85
Chemical nature and structure of organic coating of quantum dots is crucial for their application in imaging diagnostics. Int J Nanomedicine (2011) 0.85
Lipid-calcium phosphate nanoparticles for delivery to the lymphatic system and SPECT/CT imaging of lymph node metastases. Biomaterials (2014) 0.85
Optimizing Druggability through Liposomal Formulations: New Approaches to an Old Concept. ISRN Pharm (2012) 0.84
Nanogel Carrier Design for Targeted Drug Delivery. J Mater Chem B Mater Biol Med (2014) 0.83
PEGylated cationic liposome-DNA complexation in brine is pathway-dependent. Biochim Biophys Acta (2013) 0.83
Intelligent design of multifunctional lipid-coated nanoparticle platforms for cancer therapy. Ther Deliv (2012) 0.83
Liposome-Based Adjuvants for Subunit Vaccines: Formulation Strategies for Subunit Antigens and Immunostimulators. Pharmaceutics (2016) 0.83
Multifunctional peptide-PEG intercalating conjugates: programmatic of gene delivery to the blood-brain barrier. Pharm Res (2010) 0.82
Zwitterionic chitosan-polyamidoamine dendrimer complex nanoparticles as a pH-sensitive drug carrier. Mol Pharm (2013) 0.82
Molecular targeting of liposomal nanoparticles to tumor microenvironment. Int J Nanomedicine (2012) 0.82
Modification of polyethylene glycol onto solid lipid nanoparticles encapsulating a novel chemotherapeutic agent (PK-L4) to enhance solubility for injection delivery. Int J Nanomedicine (2012) 0.81
A computational framework for identifying design guidelines to increase the penetration of targeted nanoparticles into tumors. Nano Today (2013) 0.80
Synthesis and characterization of lipid-polymer hybrid nanoparticles with pH-triggered poly(ethylene glycol) shedding. Langmuir (2011) 0.80
Antitumor and antimetastasis effects of carboplatin liposomes with polyethylene glycol-2000 on SGC-7901 gastric cell-bearing nude mice. Oncol Lett (2014) 0.80
A Simple and Efficient Synthesis of an Acid-labile Polyphosphoramidate by Organobase-catalyzed Ring-Opening Polymerization and Transformation to Polyphosphoester Ionomers by Acid Treatment. Macromolecules (2013) 0.80
Stealth nanotubes: strategies of shielding carbon nanotubes to evade opsonization and improve biodistribution. Int J Nanomedicine (2014) 0.80
Selective non-covalent triggered release from liposomes. Chem Commun (Camb) (2012) 0.79
Recombinant Immunotoxin Therapy of Solid Tumors: Challenges and Strategies. J Basic Clin Med (2013) 0.78
Lipid nature and their influence on opening of redox-active liposomes. Langmuir (2013) 0.78
Enabling nanomaterial, nanofabrication and cellular technologies for nanoneuromedicines. Nanomedicine (2015) 0.78
Mechanisms of cooperation in cancer nanomedicine: towards systems nanotechnology. Trends Biotechnol (2014) 0.78
Extracellularly activatable nanocarriers for drug delivery to tumors. Expert Opin Drug Deliv (2014) 0.77
Effective Delivery of PEGylated siRNA-Containing Lipoplexes to Extraperitoneal Tumours following Intraperitoneal Administration. J Drug Deliv (2011) 0.77
Validation of a Janus role of methotrexate-based PEGylated chitosan nanoparticles in vitro. Nanoscale Res Lett (2014) 0.76
A new approach to reduce toxicities and to improve bioavailabilities of platinum-containing anti-cancer nanodrugs. Sci Rep (2015) 0.76
Lipid nanoparticles for gene delivery. Adv Genet (2014) 0.76
Morphological Analysis of Reticuloendothelial System in Capuchin Monkeys (Sapajus spp.) after Meso-2,3-Dimercaptosuccinic Acid (DMSA) Coated Magnetic Nanoparticles Administration. PLoS One (2015) 0.75
Nanotechnology for cancer treatment. Nanotechnol Rev (2015) 0.75
Targeting ischemic penumbra Part II: selective drug delivery using liposome technologies. J Exp Stroke Transl Med (2011) 0.75
Biodegradable micelles capable of mannose-mediated targeted drug delivery to cancer cells. Macromol Rapid Commun (2015) 0.75
Surface De-PEGylation Controls Nanoparticle-Mediated siRNA Delivery In Vitro and In Vivo. Theranostics (2017) 0.75
Reducible PEG-POD/DNA Nanoparticles for Gene Transfer In Vitro and In Vivo: Application in a Mouse Model of Age-Related Macular Degeneration. Mol Ther Nucleic Acids (2017) 0.75
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release (2000) 14.89
Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov (2005) 10.97
Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res (1989) 5.62
PEGylation, successful approach to drug delivery. Drug Discov Today (2005) 4.56
Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities. Adv Drug Deliv Rev (2003) 3.25
Sterically stabilized liposomes. Biochim Biophys Acta (1992) 3.10
"SMART" drug delivery systems: double-targeted pH-responsive pharmaceutical nanocarriers. Bioconjug Chem (2006) 2.58
Unraveling the role of proteases in cancer. Clin Chim Acta (2000) 2.27
Liposome-cell interactions in vitro: effect of liposome surface charge on the binding and endocytosis of conventional and sterically stabilized liposomes. Biochemistry (1998) 1.96
On the formulation of pH-sensitive liposomes with long circulation times. Adv Drug Deliv Rev (2004) 1.71
Lactosylated poly(ethylene glycol)-siRNA conjugate through acid-labile beta-thiopropionate linkage to construct pH-sensitive polyion complex micelles achieving enhanced gene silencing in hepatoma cells. J Am Chem Soc (2005) 1.66
Chemical approaches to triggerable lipid vesicles for drug and gene delivery. Acc Chem Res (2003) 1.64
Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial? Clin Cancer Res (1999) 1.54
Cytosolic drug delivery using pH- and light-sensitive liposomes. Adv Drug Deliv Rev (1999) 1.52
Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid. Gene Ther (2006) 1.51
A dominant role of acid pH in inflammatory excitation and sensitization of nociceptors in rat skin, in vitro. J Neurosci (1995) 1.41
Toward synthetic viruses: endosomal pH-triggered deshielding of targeted polyplexes greatly enhances gene transfer in vitro and in vivo. Mol Ther (2005) 1.33
Stabilized plasmid-lipid particles: construction and characterization. Gene Ther (1999) 1.33
Steric stabilization of fusogenic liposomes by a low-pH sensitive PEG--diortho ester--lipid conjugate. Bioconjug Chem (2001) 1.28
Transfection and physical properties of various saccharide, poly(ethylene glycol), and antibody-derivatized polyethylenimines (PEI). J Gene Med (2000) 1.27
Cathepsin B in synovial cells at the site of joint destruction in rheumatoid arthritis. Arthritis Rheum (1991) 1.26
Synthesis and characterization of novel poly(ethylene glycol)-lipid conjugates suitable for use in drug delivery. J Control Release (2006) 1.23
Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycol-lipid conjugates and nucleic Acid. J Pharmacol Exp Ther (2004) 1.23
A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells. Biochim Biophys Acta (1995) 1.21
New amphipatic polymer-lipid conjugates forming long-circulating reticuloendothelial system-evading liposomes. Bioconjug Chem (1995) 1.20
Poly(ethylene glycol)--lipid conjugates regulate the calcium-induced fusion of liposomes composed of phosphatidylethanolamine and phosphatidylserine. Biochemistry (1996) 1.20
Low-pH-sensitive poly(ethylene glycol) (PEG)-stabilized plasmid nanolipoparticles: effects of PEG chain length, lipid composition and assembly conditions on gene delivery. J Gene Med (2005) 1.19
Use of poly(ethylene glycol)-lipid conjugates to regulate the surface attributes and transfection activity of lipid-DNA particles. J Pharm Sci (2000) 1.18
Amphiphilic vinyl polymers effectively prolong liposome circulation time in vivo. Biochim Biophys Acta (1994) 1.17
Acid-triggered release via dePEGylation of DOPE liposomes containing acid-labile vinyl ether PEG-lipids. J Control Release (2003) 1.16
Protective copolymers for nonviral gene vectors: synthesis, vector characterization and application in gene delivery. Gene Ther (2000) 1.16
Exploitation of intracellular pH gradients in the cellular delivery of macromolecules. J Pharm Sci (2002) 1.16
Controlling liposome blood clearance by surface-grafted polymers. Adv Drug Deliv Rev (1998) 1.15
New detachable poly(ethylene glycol) conjugates: cysteine-cleavable lipopolymers regenerating natural phospholipid, diacyl phosphatidylethanolamine. Bioconjug Chem (1999) 1.13
pH-responsive sulfonamide/PEI system for tumor specific gene delivery: an in vitro study. Biomacromolecules (2006) 1.13
Enzyme-activated targeting of liposomes. Adv Drug Deliv Rev (2001) 1.12
Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes. Mol Ther (2005) 1.11
Comparison of different hydrophobic anchors conjugated to poly(ethylene glycol): effects on the pharmacokinetics of liposomal vincristine. Biochim Biophys Acta (1998) 1.11
Controlled destabilization of a liposomal drug delivery system enhances mitoxantrone antitumor activity. Nat Biotechnol (1999) 1.10
Targeted delivery and triggered release of liposomal doxorubicin enhances cytotoxicity against human B lymphoma cells. Biochim Biophys Acta (2001) 1.09
Interbilayer transfer of phospholipid-anchored macromolecules via monomer diffusion. Biochemistry (1993) 1.09
Liposomes with detachable polymer coating: destabilization and fusion of dioleoylphosphatidylethanolamine vesicles triggered by cleavage of surface-grafted poly(ethylene glycol). FEBS Lett (1996) 1.08
Evaluation of circulation profiles of liposomes coated with hydrophilic polymers having different molecular weights in rats. J Control Release (2001) 1.04
Characterization of the inhibitory effect of PEG-lipid conjugates on the intracellular delivery of plasmid and antisense DNA mediated by cationic lipid liposomes. Biochim Biophys Acta (2002) 1.03
Stabilized plasmid-lipid particles: pharmacokinetics and plasmid delivery to distal tumors following intravenous injection. J Drug Target (2000) 1.00
Stabilized plasmid-lipid particles for systemic gene therapy. Gene Ther (2000) 0.99
Low-pH-sensitive PEG-stabilized plasmid-lipid nanoparticles: preparation and characterization. Bioconjug Chem (2003) 0.97
Interference of poly(ethylene glycol)-lipid analogues with cationic-lipid-mediated delivery of oligonucleotides; role of lipid exchangeability and non-lamellar transitions. Biochem J (2002) 0.97
Pharmaco attributes of dioleoylphosphatidylethanolamine/cholesterylhemisuccinate liposomes containing different types of cleavable lipopolymers. Pharmacol Res (2004) 0.97
Stabilized plasmid-lipid particles containing PEG-diacylglycerols exhibit extended circulation lifetimes and tumor selective gene expression. Biochim Biophys Acta (2005) 0.97
Mechanism of pH-triggered collapse of phosphatidylethanolamine liposomes stabilized by an ortho ester polyethyleneglycol lipid. Biophys J (2003) 0.96
pH-sensitive PEG lipids containing orthoester linkers: new potential tools for nonviral gene delivery. J Control Release (2004) 0.95
Synthesis of acid-labile diplasmenyl lipids for drug and gene delivery applications. Chem Phys Lipids (1999) 0.95
Novel intracellular delivery system of antisense oligonucleotide by self-assembled hybrid micelles composed of DNA/PEG conjugate and cationic fusogenic peptide. Bioconjug Chem (2003) 0.94
A novel family of L-amino acid-based biodegradable polymer-lipid conjugates for the development of long-circulating liposomes with effective drug-targeting capacity. Bioconjug Chem (2003) 0.94
Stabilized plasmid-lipid particles: factors influencing plasmid entrapment and transfection properties. Biochim Biophys Acta (1999) 0.94
pH triggered release of protective poly(ethylene glycol)-b-polycation copolymers from liposomes. Biomaterials (2005) 0.92
Polymer-coated polyethylenimine/DNA complexes designed for triggered activation by intracellular reduction. J Gene Med (2004) 0.91
Interactions between pH-sensitive liposomes and model membranes. Biophys Chem (2003) 0.91
Immunogenicity and pharmacokinetic attributes of poly(ethylene glycol)-grafted immunoliposomes. Biochim Biophys Acta (1997) 0.90
Prevention of antibody-mediated elimination of ligand-targeted liposomes by using poly(ethylene glycol)-modified lipids. J Pharmacol Exp Ther (2002) 0.90
Poly(ethylene oxide sulfide): new poly(ethylene glycol) derivatives degradable in reductive conditions. Biomacromolecules (2005) 0.89
pH-responsive oligodeoxynucleotide (ODN)-poly(ethylene glycol) conjugate through acid-labile beta-thiopropionate linkage: preparation and polyion complex micelle formation. Biomacromolecules (2003) 0.89
Screening effect of PEG on avidin binding to liposome surface receptors. Int J Pharm (2001) 0.89
Poly(Hpma)-coated liposomes demonstrate prolonged circulation in mice. J Liposome Res (2001) 0.88
Intermembrane transfer of polyethylene glycol-modified phosphatidylethanolamine as a means to reveal surface-associated binding ligands on liposomes. Biochim Biophys Acta (2001) 0.87
Sodium ion/hydrogen ion exchange inhibition: a new pharmacologic approach to myocardial ischemia and reperfusion injury. J Clin Pharmacol (1998) 0.86
Stabilized plasmid-lipid particles: a systemic gene therapy vector. Methods Enzymol (2002) 0.86
A reduction-triggered delivery by a liposomal carrier possessing membrane-permeable ligands and a detachable coating. Colloids Surf B Biointerfaces (2006) 0.85
Smart polyion complex micelles for targeted intracellular delivery of PEGylated antisense oligonucleotides containing acid-labile linkages. Chembiochem (2005) 0.84
Enzymatic degradation of liposome-grafted poly(hydroxyethyl L-glutamine). Bioconjug Chem (2005) 0.81
Programmable fusogenic vesicles for intracellular delivery of antisense oligodeoxynucleotides: enhanced cellular uptake and biological effects. Biochim Biophys Acta (2001) 0.80
Effects of phosphatidylserine on membrane incorporation and surface protection properties of exchangeable poly(ethylene glycol)-conjugated lipids. Biochim Biophys Acta (2002) 0.79
Characterization and transfection properties of lipoplexes stabilized with novel exchangeable polyethylene glycol-lipid conjugates. Biochim Biophys Acta (2004) 0.79
Characterisation of biotinylated liposomes for in vivo targeting applications. FEBS Lett (1993) 0.77
Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res (2004) 3.03
Endosomal escape pathways for delivery of biologicals. J Control Release (2010) 2.90
Identification of formaldehyde-induced modifications in proteins: reactions with model peptides. J Biol Chem (2003) 2.60
Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J Control Release (2011) 2.37
MR molecular imaging and fluorescence microscopy for identification of activated tumor endothelium using a bimodal lipidic nanoparticle. FASEB J (2005) 2.03
Targeting of angiogenic endothelial cells at sites of inflammation by dexamethasone phosphate-containing RGD peptide liposomes inhibits experimental arthritis. Arthritis Rheum (2006) 1.98
Quantum dots with a paramagnetic coating as a bimodal molecular imaging probe. Nano Lett (2006) 1.98
Theranostic nanomedicine. Acc Chem Res (2011) 1.84
Polymeric micelles in anticancer therapy: targeting, imaging and triggered release. Pharm Res (2010) 1.83
A new xenograft model for graft-versus-host disease by intravenous transfer of human peripheral blood mononuclear cells in RAG2-/- gammac-/- double-mutant mice. Blood (2003) 1.74
Reduction-sensitive polymers and bioconjugates for biomedical applications. Biomaterials (2009) 1.70
Biodegradable polymers as non-viral carriers for plasmid DNA delivery. J Control Release (2007) 1.64
Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin. J Control Release (2003) 1.63
Anti-tumor activity of liposomal glucocorticoids: The relevance of liposome-mediated drug delivery, intratumoral localization and systemic activity. J Control Release (2010) 1.63
Nanotheranostics and image-guided drug delivery: current concepts and future directions. Mol Pharm (2010) 1.60
Novel bioreducible poly(amido amine)s for highly efficient gene delivery. Bioconjug Chem (2007) 1.56
25th anniversary article: Engineering hydrogels for biofabrication. Adv Mater (2013) 1.54
Artificial viruses: a nanotechnological approach to gene delivery. Nat Rev Drug Discov (2006) 1.52
Constrained and UV-activatable cell-penetrating peptides for intracellular delivery of liposomes. J Control Release (2012) 1.48
A liposomal system for contrast-enhanced magnetic resonance imaging of molecular targets. Bioconjug Chem (2004) 1.47
Hydrogels for protein delivery. Chem Rev (2012) 1.44
Temperature-, concentration- and cholesterol-dependent translocation of L- and D-octa-arginine across the plasma and nuclear membrane of CD34+ leukaemia cells. Biochem J (2007) 1.44
Intratumoral administration of holmium-166 acetylacetonate microspheres: antitumor efficacy and feasibility of multimodality imaging in renal cancer. PLoS One (2013) 1.42
Hydrogels as extracellular matrices for skeletal tissue engineering: state-of-the-art and novel application in organ printing. Tissue Eng (2007) 1.42
In situ gelling hydrogels for pharmaceutical and biomedical applications. Int J Pharm (2008) 1.41
Complete remission of experimental arthritis by joint targeting of glucocorticoids with long-circulating liposomes. Arthritis Rheum (2003) 1.39
The effect of photopolymerization on stem cells embedded in hydrogels. Biomaterials (2008) 1.39
Molecular imaging of tumor angiogenesis using alphavbeta3-integrin targeted multimodal quantum dots. Angiogenesis (2008) 1.37
Passive versus active tumor targeting using RGD- and NGR-modified polymeric nanomedicines. Nano Lett (2014) 1.37
Identification of formaldehyde-induced modifications in proteins: reactions with insulin. Bioconjug Chem (2006) 1.37
Cyclodextrin-based polymeric materials: synthesis, properties, and pharmaceutical/biomedical applications. Biomacromolecules (2009) 1.33
Effect of physicochemical modification on the biodistribution and tumor accumulation of HPMA copolymers. J Control Release (2005) 1.30
Hydrolysable core-crosslinked thermosensitive polymeric micelles: synthesis, characterisation and in vivo studies. Biomaterials (2007) 1.30
Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status. Adv Drug Deliv Rev (2013) 1.29
Multimodal clinical imaging to longitudinally assess a nanomedical anti-inflammatory treatment in experimental atherosclerosis. Mol Pharm (2010) 1.28
Linear poly(amido amine)s with secondary and tertiary amino groups and variable amounts of disulfide linkages: synthesis and in vitro gene transfer properties. J Control Release (2006) 1.26
Organ printing: the future of bone regeneration? Trends Biotechnol (2011) 1.26
Chitosan-based delivery systems for protein therapeutics and antigens. Adv Drug Deliv Rev (2009) 1.26
Effect of cationic carriers on the pharmacokinetics and tumor localization of nucleic acids after intravenous administration. Int J Pharm (2006) 1.25
Synthesis and characterization of hyperbranched polyglycerol hydrogels. Biomaterials (2006) 1.24
Simultaneous delivery of doxorubicin and gemcitabine to tumors in vivo using prototypic polymeric drug carriers. Biomaterials (2009) 1.24
The immunogenicity of polyethylene glycol: facts and fiction. Pharm Res (2013) 1.24
Multifunctional nanoemulsion platform for imaging guided therapy evaluated in experimental cancer. ACS Nano (2011) 1.23
Early in vivo assessment of angiostatic therapy efficacy by molecular MRI. FASEB J (2007) 1.23
Personalized nanomedicine. Clin Cancer Res (2012) 1.22
Bioreducible poly(amido amine)s with oligoamine side chains: synthesis, characterization, and structural effects on gene delivery. J Control Release (2007) 1.21
The therapeutic equivalence of complex drugs. Regul Toxicol Pharmacol (2010) 1.20
Noninvasive optical imaging of nanomedicine biodistribution. ACS Nano (2012) 1.19
Recent progress in nanomedicine: therapeutic, diagnostic and theranostic applications. Curr Opin Biotechnol (2013) 1.19
Nonnatural amino acids for site-specific protein conjugation. Bioconjug Chem (2009) 1.18
Core-crosslinked polymeric micelles with controlled release of covalently entrapped doxorubicin. Biomaterials (2010) 1.17
How to screen non-viral gene delivery systems in vitro? J Control Release (2011) 1.17
A versatile family of degradable non-viral gene carriers based on hyperbranched poly(ester amine)s. J Control Release (2005) 1.16
Pulsed in vitro release and in vivo behavior of exploding microcapsules. J Control Release (2009) 1.15
Annexin A5-conjugated quantum dots with a paramagnetic lipidic coating for the multimodal detection of apoptotic cells. Bioconjug Chem (2006) 1.14
Effects of Na+/H+ exchanger inhibitors on subcellular localisation of endocytic organelles and intracellular dynamics of protein transduction domains HIV-TAT peptide and octaarginine. J Control Release (2006) 1.14
Preparation and characterization of protein-loaded N-trimethyl chitosan nanoparticles as nasal delivery system. J Control Release (2005) 1.13
Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis. Brain (2003) 1.11
Effect of intratumoral injection on the biodistribution and the therapeutic potential of HPMA copolymer-based drug delivery systems. Neoplasia (2006) 1.11
Endosomal escape of polymeric gene delivery complexes is not always enhanced by polymers buffering at low pH. Biomacromolecules (2004) 1.09
Enhanced engraftment of human cells in RAG2/gammac double-knockout mice after treatment with CL2MDP liposomes. Exp Hematol (2004) 1.08
The nuclear pore complex: the gateway to successful nonviral gene delivery. Pharm Res (2006) 1.07
Gold nanocrystal labeling allows low-density lipoprotein imaging from the subcellular to macroscopic level. ACS Nano (2013) 1.07
Liposome-encapsulated prednisolone phosphate inhibits growth of established tumors in mice. Neoplasia (2005) 1.07
Annexin A5-functionalized bimodal lipid-based contrast agents for the detection of apoptosis. Bioconjug Chem (2006) 1.07
Degradable-brushed pHEMA-pDMAEMA synthesized via ATRP and click chemistry for gene delivery. Bioconjug Chem (2007) 1.06
Targeting anti-transferrin receptor antibody (OX26) and OX26-conjugated liposomes to brain capillary endothelial cells using in situ perfusion. J Cereb Blood Flow Metab (2004) 1.06
Targeting tumor antigens to dendritic cells using particulate carriers. J Control Release (2012) 1.05
Effects of treatment with small interfering RNA on joint inflammation in mice with collagen-induced arthritis. Arthritis Rheum (2005) 1.04
Hydrogels for protein delivery in tissue engineering. J Control Release (2012) 1.04
Contribution of classic and alternative effector pathways in peanut-induced anaphylactic responses. PLoS One (2011) 1.04
Fusogenic peptides enhance endosomal escape improving siRNA-induced silencing of oncogenes. Int J Pharm (2006) 1.04
Interaction of dendritic cells with antigen-containing liposomes: effect of bilayer composition. Vaccine (2004) 1.03
Glycan-modified liposomes boost CD4+ and CD8+ T-cell responses by targeting DC-SIGN on dendritic cells. J Control Release (2012) 1.02
Functional characterization of an endosome-disruptive peptide and its application in cytosolic delivery of immunoliposome-entrapped proteins. J Biol Chem (2002) 1.02
Self-assembly of recombinant amphiphilic oligopeptides into vesicles. Biomacromolecules (2007) 1.02
Sensitive spectroscopic detection of large and denatured protein aggregates in solution by use of the fluorescent dye Nile red. J Fluoresc (2007) 1.02
Challenges for the effective molecular imprinting of proteins. Biomaterials (2011) 1.02
Effect of radiotherapy and hyperthermia on the tumor accumulation of HPMA copolymer-based drug delivery systems. J Control Release (2006) 1.02
Shifting paradigms: biopharmaceuticals versus low molecular weight drugs. Int J Pharm (2003) 1.02
Superparamagnetic iron oxide nanoparticles encapsulated in biodegradable thermosensitive polymeric micelles: toward a targeted nanomedicine suitable for image-guided drug delivery. Langmuir (2009) 1.02
Local perivascular delivery of anti-restenotic agents from a drug-eluting poly(epsilon-caprolactone) stent cuff. Biomaterials (2005) 1.01
Synthesis and applications of biomedical and pharmaceutical polymers via click chemistry methodologies. Bioconjug Chem (2009) 1.01
Therapeutic application of long-circulating liposomal glucocorticoids in auto-immune diseases and cancer. J Liposome Res (2006) 1.01
Functional aliphatic polyesters for biomedical and pharmaceutical applications. J Control Release (2011) 1.01
Imaging the efficacy of anti-inflammatory liposomes in a rabbit model of atherosclerosis by non-invasive imaging. Methods Enzymol (2012) 1.01
Gold nanoparticles in theranostic oncology: current state-of-the-art. Expert Opin Drug Deliv (2012) 0.99
Thermosensitive and biodegradable polymeric micelles for paclitaxel delivery. J Control Release (2005) 0.98